Mezigdomide combinations show promising activity in relapsed/refractory multiple myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses emerging data on mezigdomide-based therapy for relapsed/refractory multiple myeloma. He highlights encouraging efficacy and tolerability findings from clinical trials evaluating mezigdomide in combination with carfilzomib and dexamethasone, including activity in lenalidomide-refractory and difficult-to-treat patient populations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.